Transgene SA - Asset Resilience Ratio
Transgene SA (TNG) has an Asset Resilience Ratio of 75.78% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TNG current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Transgene SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Transgene SA balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Transgene SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TNG long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €105.20 Million | 75.78% |
| Total Liquid Assets | €105.20 Million | 75.78% |
Asset Resilience Insights
- Very High Liquidity: Transgene SA maintains exceptional liquid asset reserves at 75.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Transgene SA Industry Peers by Asset Resilience Ratio
Compare Transgene SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Transgene SA (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Transgene SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.78% | €105.20 Million ≈ $122.99 Million |
€138.83 Million ≈ $162.30 Million |
+42.03pp |
| 2022-12-31 | 33.75% | €22.42 Million ≈ $26.21 Million |
€66.44 Million ≈ $77.67 Million |
-9.12pp |
| 2021-12-31 | 42.87% | €43.66 Million ≈ $51.04 Million |
€101.84 Million ≈ $119.06 Million |
+18.21pp |
| 2020-12-31 | 24.67% | €21.08 Million ≈ $24.64 Million |
€85.45 Million ≈ $99.90 Million |
-11.73pp |
| 2019-12-31 | 36.40% | €42.03 Million ≈ $49.14 Million |
€115.48 Million ≈ $135.00 Million |
+22.56pp |
| 2018-12-31 | 13.83% | €15.02 Million ≈ $17.55 Million |
€108.54 Million ≈ $126.90 Million |
-25.58pp |
| 2017-12-31 | 39.42% | €39.76 Million ≈ $46.49 Million |
€100.87 Million ≈ $117.93 Million |
-2.35pp |
| 2016-12-31 | 41.77% | €51.35 Million ≈ $60.04 Million |
€122.95 Million ≈ $143.74 Million |
+13.65pp |
| 2015-12-31 | 28.12% | €28.36 Million ≈ $33.16 Million |
€100.87 Million ≈ $117.93 Million |
-16.17pp |
| 2014-12-31 | 44.29% | €62.42 Million ≈ $72.98 Million |
€140.95 Million ≈ $164.79 Million |
+10.34pp |
| 2013-12-31 | 33.95% | €42.72 Million ≈ $49.95 Million |
€125.85 Million ≈ $147.13 Million |
-20.13pp |
| 2012-12-31 | 54.08% | €86.78 Million ≈ $101.45 Million |
€160.46 Million ≈ $187.60 Million |
-17.09pp |
| 2011-12-31 | 71.17% | €137.77 Million ≈ $161.07 Million |
€193.58 Million ≈ $226.32 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more